ACC/AHA Perioperative Cardiovascular Evaluation for Noncardiac Surgery
The 2024 ACC/AHA guidelines provide a stepwise, risk-stratified approach to perioperative cardiovascular evaluation that prioritizes functional capacity assessment and selective testing over routine preoperative workup, with major updates to medication management and timing of surgery after coronary stents. 1
Stepwise Risk Stratification Algorithm
The evaluation follows a structured 6-step approach:
Step 1: Determine Urgency
- Emergency surgery proceeds immediately with appropriate monitoring based on clinical assessment
- Urgent/elective surgery continues to Step 2 2
Step 2: Screen for Acute Coronary Syndrome
- If ACS present, refer for cardiology evaluation and guideline-directed medical therapy before proceeding
- If no ACS, advance to Step 3 2
Step 3: Estimate Combined Clinical/Surgical Risk
- Use the ACS NSQIP risk calculator (http://www.riskcalculator.facs.org) or combine RCRI with surgical risk
- RCRI factors: coronary artery disease, heart failure, cerebrovascular disease, diabetes mellitus, renal insufficiency (creatinine >2.0 mg/dL), high-risk surgery 2
- Elevated risk defined as >1% chance of major adverse cardiovascular events (MACE) 1
Step 4: Low Risk (<1% MACE)
- Proceed directly to surgery without further testing 2
Step 5: Elevated Risk - Assess Functional Capacity
- Use Duke Activity Status Index (DASI) or objective measure
- ≥4 METs (can climb flight of stairs, walk up hill, do heavy housework) = proceed to surgery without testing 2
- <4 METs or unknown capacity = advance to Step 6
Step 6: Poor/Unknown Functional Capacity
- Determine if testing will change management (willingness to undergo revascularization, alter surgical approach, modify perioperative care)
- If yes: pharmacological stress testing appropriate
- If abnormal stress test: consider coronary angiography based on extent of abnormality 2
Surgical Risk Classification
High Risk (>5% cardiac risk):
- Emergency major operations (especially elderly)
- Aortic and major vascular surgery
- Peripheral vascular surgery
- Prolonged procedures with large fluid shifts/blood loss 3
Intermediate Risk (<5% cardiac risk):
- Carotid endarterectomy
- Head/neck surgery
- Intraperitoneal/intrathoracic surgery
- Orthopedic surgery
- Prostate surgery 3
Low Risk (<1% cardiac risk):
- Endoscopic procedures
- Superficial procedures
- Cataract surgery
- Breast surgery
- Do not require further preoperative cardiac testing 3
Preoperative Testing Recommendations
12-Lead ECG (Class IIa):
- Reasonable for patients with known coronary disease, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, or structural heart disease
- Exception: not needed for low-risk surgery 2
Stress Testing:
- NOT indicated for low-risk surgery regardless of risk factors
- Consider only if: elevated risk + poor functional capacity + results would change management
- Pharmacological stress preferred; exercise stress reasonable if functional capacity unknown 2
Routine Coronary Revascularization:
- Class III (No Benefit): NOT recommended exclusively to reduce perioperative cardiac events 2, 4
- Only perform if indicated by existing guidelines independent of planned surgery 2
Timing of Surgery After Coronary Intervention
Critical timing requirements (Class I recommendations):
After Balloon Angioplasty:
- Delay surgery ≥14 days 2
After Bare-Metal Stent (BMS):
- Delay surgery ≥30 days 2
After Drug-Eluting Stent (DES):
- Optimal delay: 365 days (Class I) 2
- May consider after 180 days if risk is acceptable (Class IIb) 2, 4
Class III (Harm) - DO NOT perform elective surgery:
- Within 30 days of BMS if DAPT must be discontinued
- Within 12 months of DES if DAPT must be discontinued
- Within 14 days of balloon angioplasty if aspirin must be discontinued 2
Perioperative Medication Management
Beta Blockers
Class I (Continue):
Class IIa:
Class IIb (May be reasonable):
- Patients with intermediate/high-risk preoperative tests
- Patients with ≥3 RCRI factors
- Start >1 day before surgery to assess tolerability 2, 4
Class III (Harm):
- DO NOT start beta blockers on day of surgery - associated with increased stroke (1.0% vs 0.5%) and mortality (3.1% vs 2.3%) 2, 4
Statins
Class I:
Class IIa:
Class IIb:
- May consider initiating in patients with clinical risk factors undergoing elevated-risk procedures 2
ACE Inhibitors/ARBs
Class IIa:
- Continuation is reasonable perioperatively 2, 4
- Reasonable to restart as soon as clinically feasible postoperatively 2, 4
Caveat: Associated with increased intraoperative hypotension risk, particularly in older adults (≥65 years) - consider holding in high-risk patients 1
Antiplatelet Therapy
Class I (Mandatory continuation):
- Continue DAPT during first 4-6 weeks after BMS or DES implantation for urgent surgery (unless bleeding risk outweighs stent thrombosis benefit) 2, 4
- If P2Y12 inhibitor discontinued, continue aspirin and restart P2Y12 inhibitor ASAP postoperatively 2, 4
- Management determined by consensus of surgeon, anesthesiologist, cardiologist, and patient 2, 4
Class IIb:
- May be reasonable to continue aspirin in patients without prior stenting when cardiac event risk outweighs bleeding risk 2, 4
Class III (No Benefit):
- Initiation or continuation of aspirin NOT beneficial in elective noncardiac noncarotid surgery without prior stenting 2, 4
Alpha-2 Agonists
Class III (No Benefit):
Hypertension Management
Class IIa:
- Continue medical therapy for hypertension throughout perioperative period in most patients 1
Class IIb:
- May consider deferring surgery if recent poorly controlled hypertension (SBP ≥180 or DBP ≥110 mm Hg) in patients with cardiovascular risk factors undergoing elevated-risk surgery 1
Intraoperative Blood Pressure (Class I):
- Maintain MAP ≥60-65 mm Hg or SBP ≥90 mm Hg to reduce myocardial injury risk 1
Common Pitfalls to Avoid
- Ordering routine stress tests in low-risk surgery - wastes resources and delays surgery without benefit
- Starting beta blockers on day of surgery - increases stroke and mortality risk
- Performing prophylactic coronary revascularization - CARP trial showed no benefit 2
- Scheduling elective surgery too soon after stent placement - dramatically increases stent thrombosis risk
- Discontinuing chronic beta blockers perioperatively - increases rebound ischemia risk
- Stopping statins perioperatively - associated with worse outcomes
- Extensive preoperative testing in asymptomatic patients with good functional capacity - functional capacity ≥4 METs is highly predictive of low risk
Key Evidence Considerations
The 2024 guidelines 1 represent the most current evidence and supersede the 2014 guidelines 2. The systematic review on beta blockers revealed that while they reduce cardiac events, they increase stroke and bradycardia risk, particularly when started acutely 4. The CARP trial definitively showed no benefit of prophylactic revascularization 2. Registry data consistently demonstrates increased complications when surgery occurs too soon after coronary stenting, particularly with premature DAPT discontinuation 2.
The modern approach emphasizes risk stratification over routine testing, functional capacity assessment over stress testing, and continuation of evidence-based chronic medications over initiation of new perioperative therapies.